Convergent Therapeutics Announces Positive Phase 2 Data at ASCO 2026 Showing Promising Anti-Tumor Activity, Durability, and Favorable Tolerability for CONV01-α in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Results from largest U.S. prospective Phase 2 dataset for an alpha radiopharmaceutical therapyin Lu-PSMA-Exposed mCRPC show CONV01-α can be safely administered to patients whose tumors have progressed following Lu-177-PSMA (PLUVICTO), a growing population where no standard of care exists
Emerging durability observed with median radiographic progression-free survival (rPFS) of 8.4 months in the target dose range
CONV01-α continues to show differentiated biodistribution compared to radioligands, with strong tumor uptake and retention, and no kidney uptake or salivary gland exposure; No renal toxicity or high-grade xerostomia observed
Study conducted across leading U.S. cancer centers with high purity Actinium (Ac-225) drug supply
